-

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq Capital Market has been approved by Nasdaq Listing Qualifications. This transition allows IPA an additional 180-day compliance period, until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share.

The Company's common stock will transfer from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on February 21, 2025. This move is in accordance with Nasdaq’s Listing Rules and maintains IPA's listing while the Company continues executing its strategic initiatives.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutic research and technology company specializing in AI-driven antibody discovery and development. Through its subsidiaries—including Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.—IPA delivers an end-to-end solution for the development of next-generation antibody therapeutics. The company integrates systems biology, multi-omics modeling, and artificial intelligence to enable the discovery of highly specialized, fully human therapeutic antibodies tailored to challenging disease targets.

For more information, visit www.ipatherapeutics.com

Contacts

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA

Release Versions
$Cashtags

Contacts

Social Media Profiles
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Announces Results of 2026 Annual General Meeting of Shareholders

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ: HYFT), a Bio-Native AI company, today announced the voting results of its 2026 Annual General Meeting of Shareholders held on November 17, 2026. A total of 18,619,753 common shares were represented by proxy at the meeting, representing 39.13% of the 47,574,512 common shares issued and outstanding as of the October 13, 2026 record date. Shareholders elected Dr. Jennifer L. Bath, Jon Lieber and Kim Remi...

MindWalk Closes US$30 Million Senior Unsecured Revolving Credit Facility

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a definitive senior unsecured revolving credit agreement with Sanabil Cayman providing a committed revolving credit facility of up to US$30 million. The agreement, dated November 16, 2026, implements the binding term sheet announced on September 14, 2026. The facility is undrawn, MindWalk is under no obligation to borrow, and no fee accrues on th...

MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and ac...
Back to Newsroom